Stereotaxis And Abbott Announce Global Collaboration Combining Leading Mapping And Robotic Technologies To Improve Treatment Of Abnormal Heart Rhythms
Portfolio Pulse from Happy Mohamed
Stereotaxis (NYSE:STXS) and Abbott (NYSE:ABT) announced a global collaboration to integrate Abbott's EnSite™ X EP System with Stereotaxis' Robotic Magnetic Navigation systems. The integrated technologies are cleared for use in Europe, with additional regulatory clearances expected in the coming months.
May 19, 2023 | 12:40 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Abbott collaborates with Stereotaxis to integrate their EnSite X EP System with Robotic Magnetic Navigation systems, potentially improving treatment of abnormal heart rhythms.
Abbott's collaboration with Stereotaxis allows for the integration of their EnSite X EP System with Stereotaxis' Robotic Magnetic Navigation systems. This partnership could lead to improved treatment of abnormal heart rhythms and increased adoption of their technology, positively impacting their stock price in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100
POSITIVE IMPACT
Stereotaxis partners with Abbott to integrate their technologies, potentially improving treatment of abnormal heart rhythms and expanding market reach.
The collaboration with Abbott allows Stereotaxis to integrate their Robotic Magnetic Navigation systems with Abbott's EnSite X EP System, enhancing the treatment of abnormal heart rhythms. This partnership could lead to increased adoption of their technology and expand their market reach, positively impacting their stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100